Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering

Author's Avatar
Jul 20, 2021

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”), today announced the closing of its initial public offering (the “Offering”) of 2,300,000 ordinary shares at a public offering price of $9.50 per share.